Tags : Inotrem

PharmaShots Weekly Snapshot (January 20-24, 2020)

1. Epizyme’s Tazverik (tazemetostat) Receives the US FDA’s Accelerated Approval as the First Therapy for Epithelioid Sarcoma Published: Jan 23, 2020 | Tags: Epizyme, Tazverik, tazemetostat, Receives, US, FDA, Accelerated Approval, First Therapy, Epithelioid Sarcoma 2. Evarsana Signs an Agreement with Evoke Pharma to Commercialize Gimoti in the US Published: Jan 23, 2020 | Tags: Evarsana, Signs, […]Read More

Inotrem Signs a Worldwide License agreement with Roche Diagnostic for

Shots: Inotrem enters into a global licensing agreement with Roche Diagnostics to commercialize mechanism-based CDx test utilizing a soluble plasma protein (sTREM-1) The collaboration leads towards the enhancement of Inotrem’s approach targeting TREM-1 pathway and allows it to focus on the development of a nangibotide-based septic shock treatment LR12 (nangibotide) is the first-in-class TREM-1 inhibitor […]Read More